METHYLDOPA Drug Patent Profile
✉ Email this page to a colleague
When do Methyldopa patents expire, and what generic alternatives are available?
Methyldopa is a drug marketed by Accord Hlthcare, Chartwell Rx, Duramed Pharms Barr, Halsey, Heritage Pharma, Parke Davis, Pliva, Purepac Pharm, Rising, Roxane, Strides Pharma, Sun Pharm Industries, Superpharm, Teva, Watson Labs, Par Pharm, Dava Pharms Inc, Ivax Sub Teva Pharms, Sandoz, Abraxis Pharm, Am Regent, Baxter Hlthcare, Hospira, Marsam Pharms Llc, Smith And Nephew, and Teva Parenteral. and is included in ninety-nine NDAs.
The generic ingredient in METHYLDOPA is methyldopate hydrochloride. There are three drug master file entries for this compound. Additional details are available on the methyldopate hydrochloride profile page.
Summary for METHYLDOPA
US Patents: | 0 |
Applicants: | 26 |
NDAs: | 99 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Clinical Trials: | 18 |
Patent Applications: | 4,212 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for METHYLDOPA |
What excipients (inactive ingredients) are in METHYLDOPA? | METHYLDOPA excipients list |
DailyMed Link: | METHYLDOPA at DailyMed |
Recent Clinical Trials for METHYLDOPA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Federal University of Paraíba | Phase 4 |
Assiut University | Phase 2 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
Pharmacology for METHYLDOPA
Drug Class | Central alpha-2 Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha2-Agonists |